Three years clinical observation on Telbivudine in the treatment of chronic hepatits B LIU Xiaoqin，ZHANG Dazhi，GUO Shuhua

Abstract:

Objective：To investigate the efficacy and safety of applying Telbivudine in the treatment of chronic hepatitis B（CHB） for consecutive 3 years. Methods：Totally 62 patients with CHB who received monotherapy of Telbivudine in the department of infectious diseases in the second affiliated hospital of Chongqing medical university took Telbivudine 600 mg orally once per day. The virology，serology and biochemical indicators of 62 patients were detected and analyzed before and at the 156th week after the treatment. The 62 patients who received the treatment for 3 years were divided into two groups according to the hepatitis B virus（HBV） DNA level（＜lg3 copy/ml and ≥lg3 copy/ml） and comparison was made at the 156th week during the treatment in order to know the ef－ficacy and safety of the treatment. Chi-square test or calibration chi-square test was applied to do the efficacy comparison. Results：After 156 weeks of treatment，HBV DNA negative rate was 79.0％，Alanine aminotransferase（ALT） normalization rate was 72.6％，HBeAg seroconversion rate was 39.7％ and drug resistant rate was 11.3％. In HBeAg-positive patients（with HBV DNA